US 12,767,728 B2Granted

Bispecific factor VIII mimetic antibodies

AssigneeNovo Nordisk A/S

InventorsKasper Lamberth, Jacob Lund, Gustav Roeder, Bjarne Gram Hansen, Per J. Greisen, Nikolai Lorenzen

Life of this patent

Estimating the term…

Abstract

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

Claims21

Dependent claims

A bispecific antibody or an antigen-binding fragment thereof capable of binding to FIX (SEQ ID NO:89) and/or the activated form thereof (FIXa), and capable of binding to FX (SEQ ID NO:90) and/or the activated form thereof (FXa),

wherein said bispecific antibody comprises an anti-FIX(a) antibody or an antigen-binding fragment thereof comprising a heavy chain and a light chain, and an anti-FX(a) antibody or an antigen-binding fragment thereof comprising a heavy chain and a light chain,
wherein
a) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
26, 27 and 28, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
30, 31 and 32, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
b) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
26, 27 and 28, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
30, 31 and 32, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
c) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
34, 35 and 36, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
38, 39 and 40, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR 1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
d) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
34, 35 and 36, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
38, 39 and 40, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
e) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
42, 43 and 44, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
46, 47 and 48, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
f) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
42, 43 and 44, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
46, 47 and 48, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
g) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
50, 51 and 52, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
54, 55 and 56, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
h) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
50, 51 and 52, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
54, 55 and 56, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
i) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
58, 59 and 60, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
62, 63 and 64, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
j) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
58, 59 and 60, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
62, 63 and 64, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
k) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
66, 67 and 68, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
70, 71 and 72, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
l) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
66, 67 and 68, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
70, 71 and 72, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
m) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
74, 75 and 76, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
78, 79 and 80, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
n) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
74, 75 and 76, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
78, 79 and 80, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
o) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
82, 83 and 84, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
86, 87 and 88, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
p) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
82, 83 and 84, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
86, 87 and 88, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively.

94 more elements

An antibody or an antigen-binding fragment thereof which is capable of binding to FIX (SEQ ID NO:89) and/or the activated form thereof (FIXa) comprising a heavy chain and a light chain wherein

a) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
26, 27 and 28, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
30, 31 and 32, respectively;
or
b) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
34, 35 and 36, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
38, 39 and 40, respectively;
or
c) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
42, 43 and 44, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
46, 47 and 48, respectively;
or
d) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
50, 51 and 52, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
54, 55 and 56, respectively;
or
e) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
58, 59 and 60, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
62, 63 and 64, respectively;
or
f) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
66, 67 and 68, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
70, 71 and 72, respectively;
or
g) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
74, 75 and 76, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
78, 79 and 80, respectively;
or
h) the heavy chain comprises CDR1-3 sequences identified by SEQ ID NOs:
82, 83 and 84, respectively, and the light chain comprises CDR1-3 sequences identified by SEQ ID NOs:
86, 87 and 88, respectively.

28 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/795,269Filed 29 Jan 2021
Priority: EP 2015460730 Jan 2020
Published: US 2025/0376538 A111 Dec 2025
Granted: 20 Oct 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07K 16/36
Against material from animals or humans: against blood coagulation factors
C07K 2317/31
Characterized by aspects of specificity or valency: multispecific
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/75
Characterized by effect upon binding to a cell or to an antigen: agonist effect on antigen

Family

US 2025/0376538 A1Pre-grant publication · published 11 Dec 2025
US 12,767,728 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

wherein said bispecific antibody comprises an anti-FIX(a) antibody or an antigen-binding fragment thereof comprising a heavy chain and a light chain, and an anti-FX(a) antibody or an antigen-binding fragment thereof comprising a heavy chain and a light chain,
wherein
a) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
26, 27 and 28, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
30, 31 and 32, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
b) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
26, 27 and 28, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
30, 31 and 32, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
c) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
34, 35 and 36, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
38, 39 and 40, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR 1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
d) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
34, 35 and 36, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
38, 39 and 40, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
e) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
42, 43 and 44, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
46, 47 and 48, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
f) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
42, 43 and 44, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
46, 47 and 48, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
g) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
50, 51 and 52, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
54, 55 and 56, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
h) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
50, 51 and 52, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
54, 55 and 56, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
i) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
58, 59 and 60, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
62, 63 and 64, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
j) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
58, 59 and 60, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
62, 63 and 64, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
k) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
66, 67 and 68, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
70, 71 and 72, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
l) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
66, 67 and 68, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
70, 71 and 72, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
m) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
74, 75 and 76, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
78, 79 and 80, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
n) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
74, 75 and 76, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
78, 79 and 80, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively;
or
o) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
82, 83 and 84, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
86, 87 and 88, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
18, 19 and 20, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
22, 23 and 24, respectively;
or
p) the heavy chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
82, 83 and 84, respectively, and the light chain of the anti-FIX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
86, 87 and 88, respectively, and the heavy chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
2, 3 and 4, respectively, and the light chain of the anti-FX(a) antibody or the antigen-binding fragment thereof comprises CDR1-3 sequences identified by SEQ ID NOs:
6, 7 and 8, respectively.

94 more elements

Facts

Application

17/795,269Filed 29 Jan 2021

Priority

EP 2015460730 Jan 2020

Published

US 2025/0376538 A111 Dec 2025

Granted

20 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07K 16/36
Against material from animals or humans: against blood coagulation factors
C07K 2317/31
Characterized by aspects of specificity or valency: multispecific
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/75
Characterized by effect upon binding to a cell or to an antigen: agonist effect on antigen